This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Newron Pharmaceuticals SpA
Drug Names(s): EMD 281014, LY2422347
Description: EMD 281014 is a novel 5-HT2A antagonist.
Eli Lilly and Merck KGaA
Eli Lilly and Merck KGaA announced on October 27, 2004, that Lilly has acquired Merck's 5-HT2a antagonist compound EMD 281014, a potential treatment for insomnia.
Under the terms of the agreement, Merck will receive an upfront payment of Euros 22.5 million (approximately $29 million) in the fourth quarter of 2004 as well as potential development and commercialization milestone payments and royalties on product sales in future periods. Lilly receives exclusive rights to develop and market this compound worldwide. Merck retains rights for potential co-promotion of the product in certain countries.
As of March 2009, Lilly's pipeline does not list LY2422347 in development. We then believe Lilly returned all rights to the drug to Merck KGaA.
Newron and Merck KGaA
In March 2011, Newron and Merck KGaA announced a broadening of the scope of their collaboration. Under the terms of the agreement, Newron received a development...See full deal structure in Biomedtracker
Partners: Merck KGaA
Additional information available to subscribers only: